Designed for payers, risk-bearing providers, and telehealth partners

Turn every restroom into a continuous early‑warning channel— not just a place members pass through.

Claims, labs, and vitals tell you who already declared themselves. UrineSense adds a passive VOC layer on top of traditional urinalysis, so you can see rising risk in your covered lives 3–4 weeks before it shows up as an avoidable ER visit, admission, or readmission.

TODAY'S REALITY High-cost events are visible only after claims or acute labs. You are managing yesterday’s risk.
WITH URINESENSE Continuous VOC trends flag rising risk between encounters. You can intervene before the event occurs.
Compare labs vs. VOC layer

Population economics

Simulated health plan with 50,000 covered lives*

VOC + labs working together

Avoidable events flagged early

600+

Members per year identified with rising VOC risk patterns.

Potential cost reduction

$10M–$15M

Modeled annual savings from avoided admissions & readmissions.

Primary use case

Early VOC flags to prioritize outreach & telehealth.

Who acts

Care managers, virtual triage teams, population health.

How labs fit in

UrineSense sends “lab nudges” when a trend crosses a threshold.

*Values are simulated to illustrate directional impact. Final results depend on deployment scale, baseline utilization, and benefits design.

A control panel for risk you cannot see today.

UrineSense turns ambient restroom traffic into a structured VOC data stream. For payers and virtual-first care teams, it behaves like an always-on “sixth sense” that feeds into your existing analytics, nurse triage, and care-management workflows.

Claims & labs

Know who crashed yesterday.

Existing infrastructure surfaces risk after the fact: ER claims, inpatient stays, abnormal labs, gaps in care, and adherence issues. You are always reacting to what just happened.

UrineSense VOC layer

See the silent build-up before the crash.

VOC fingerprints shift as metabolic stress, hydration, kidney strain, or infection risk evolves. Our models turn those shifts into a panel-level risk index you can act on weeks early.

Telehealth & care teams

Convert invisible risk into scheduled encounters.

High-risk VOC trends trigger outreach: telehealth visits, digital nudges, nurse calls, and confirmatory lab orders. Members see proactive care instead of surprise bills.

Traditional Laboratory Urinalysis (Baseline)

Nothing about UrineSense changes the lab workflow you already trust. Physical, chemical, microscopic, and culture analysis remain the gold standard for diagnosis and documentation. UrineSense simply helps you decide when to order those tests and for whom—in a more targeted, proactive way.

What urinalysis already gives you.

Standard urinalysis is a workhorse in chronic kidney disease, diabetes, hypertension, and infection management. It provides the structured lab values your actuaries, quality teams, and providers already rely on—for diagnosis, staging, and quality reporting (HEDIS, Stars, etc.).

UrineSense does not re-create these results. Instead, it acts as a continuous sensor outside the lab—pointing you toward the members who most need a formal diagnostic workup.

Physical Examination

Color, clarity, and odor provide immediate clues about hydration, blood, and infection. This is the first “visual triage” the lab performs on a specimen.

Color

Pale Yellow
Red/Brown
Dark Yellow/Orange

Clarity

Clear
Cloudy/Turbid
Foamy

Odor

Normal (Aromatic)
Foul/Pungent
Fruity/Sweet

Click an item above to see its description here.

Chemical Examination (Dipstick)

A reagent strip screens for protein, glucose, ketones, blood, and more. For your organization, these values feed directly into chronic disease programs, risk adjustment, and quality metrics.

Select a test from the chart

Detailed information about the selected chemical test will appear here.

Microscopic Examination

Cells, casts, crystals, bacteria, and yeast reinforce the diagnosis and drive precise treatment.

Click an item above to see its description here.

Culture & Sensitivity (C&S)

When infection is suspected, C&S testing identifies the organism and the right antibiotic. UrineSense can flag likely infection risk earlier, so these tests are ordered before the member lands in the ER.

1. Inoculation

Sample streaked onto agar plates.

2. Incubation

24–48 hours to allow growth.

3. Identification

Colonies counted and identified.

4. Sensitivity

Antibiotic susceptibility testing.

Sample Collection Still Matters

The accuracy of any urinalysis depends on proper collection. Whether in brick-and-mortar clinics or affiliated labs, your members follow clean-catch or 24-hour protocols as directed.

Clean-Catch Midstream (for clinics & labs)

Standard instructions: handwashing, genital cleaning, discard initial stream, collect midstream, seal container, prompt transport.

UrineSense does not change these instructions. It simply adds a separate, passive VOC reading in the restroom environment—even when no formal sample is ordered.

UrineSense: a continuous VOC signal between lab encounters.

Think of UrineSense as a low-friction, high-frequency “check engine light” that plugs into your existing data stack. Every anonymized VOC reading can be attached to a member and sent as structured data into your population health platform or telehealth stack via FHIR APIs.

80%

Simulated model accuracy in predicting at‑risk members before claims.

$10M+

Modeled annual savings from avoided admissions & readmissions.

3–4 weeks

Average early-warning window for rising VOC risk trends.

Traditional data vs VOC trend for a high-risk panel

The chart below illustrates a common situation: population-level vitals and claims look flat until the moment a member tips into crisis. VOC data (orange) reveals a rising pattern long before that point.

VOC trends cross a high‑risk threshold weeks before the next lab or claim is generated.

Traditional labs + UrineSense: how they work together.

UrineSense is not a replacement for urinalysis or bloodwork. It is a precursor signal. Labs remain the diagnostic authority; UrineSense tells you who deserves that attention first.

Dimension Traditional Lab Urinalysis UrineSense VOC Platform
Timing Episodic; ordered when symptoms appear or protocols require. Continuous or high-frequency; runs in the background.
Signal type Physical, chemical, microscopic, culture; diagnostic detail. VOC fingerprints and trends; early signal of metabolic, renal, or infectious stress.
Primary payer use Support diagnosis, adjudicate claims, and document quality measures. Rank-order risk within cohorts to prioritize outreach, telehealth, and lab spending.
Member experience Deliberate sample collection, travel to lab, wait for results. Passive in affiliated restrooms or home toilets; no behavior change.
Population view Aggregated after results are reported, coded, and paid. Near real-time VOC risk dashboard, integrated into population health platform.
Interplay Provides definitive diagnosis and treatment guidance. Sends “lab nudges” when VOC trends cross thresholds, raising the right flags at the right time.
Economic impact Costs incurred once a member is already in the medical system. Reduces avoidable ER visits, admissions, and readmissions by acting earlier.

For payers and telehealth partners, the opportunity is not to replace proven diagnostics, but to extend your field of view so that fewer members move from “quiet” to “catastrophic” without a warning.

Case study (simulated): 55‑year‑old member with rising VOC risk.

This scenario shows how UrineSense would have changed one member’s trajectory for a regional health plan.

Without UrineSense (reactive)

  • Profile: 55‑year‑old male, pre‑diabetes, mild CKD.
  • Vitals & claims: BP 128/82, A1c 6.8%, stable meds, no recent ER.
  • Last labs: 5 months ago—stable, no urgent flags.
  • Event: Presents to ER with urosepsis; admitted for 4 days, $28,000 total cost.
  • Quality & experience: Member reports “no one saw this coming.”

With UrineSense (proactive)

  • VOC trend: 3‑week upward shift in VOCs associated with infection & inflammatory stress.
  • Threshold: Risk index crosses “high” threshold 12 days before symptoms.
  • Automated action: VOC engine pushes FHIR event → population health platform → care manager queue.
  • Telehealth workflow: Nurse call + virtual visit → symptoms reviewed → urine lab ordered.
  • Outcome: UTI treated outpatient; member avoids admission; net plan savings ~$20,000.

All values are simulated for illustration only. They show how a VOC layer can shift your economics from “paying for sudden crises” toward “funding early, targeted interventions.”